DelveInsight launched a new report on “Lupus Nephritis – Epidemiology Forecast to 2030”.
DelveInsight’s ‘Lupus Nephritis – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Lupus Nephritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the facts of the report
1. As per DelveInsight analysis, the United Sates accounted for the maximum number of LN patients with 134,190 cases in 2017.
2. As per DelveInsight analysis, Italy accounted for 134,190 LN patients in 2017.
3. DelveInsight estimates, in 2017, Proteinuria associated with LN cases were found in all of the diagnosed cases, while second common manifestation in LN was microscopic hematuria with 85,882 cases (80%).
4. As per DelveInsight’s estimates, total Prevalent population of Lupus Nephritis in the 7 major markets was 190,819 in 2017,
“According to Delveinsight, Market Size of Lupus Nephritis (LN) in the 7MM was found to be $1360million in 2017.”
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease and is the most common form of lupus that can affect multiple tissues and organs. The disease is being characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations.
The primary pathological findings in patients with SLE include inflammation, vasculitis, immune complex deposition, and vasculopathy.
Lupus nephritis (LN) is a common and potentially devastating manifestation of SLE. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli.
Although LN can occur during a flare of SLE with skin manifestations or other organ system involvement, it often occurs without other clinical signs of active lupus. Thus, it is of key importance that patients with lupus have routine urine analysis with microscopy looking for protein, blood, and cellular casts. Lupus nephritis is primarily caused by the deposition of immune complexes. The size of the complexes determines the location of deposition, and therefore, leads to differences in classification (mesangial, focal, diffuse).
Request for sample pages : https://delveinsight.com/sample-request/lupus-nephritis-epidemiology-forecast
Scope of the Report
- The Lupus Nephritis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Lupus Nephritis Epidemiology Report and Model provide an overview of the risk factors and global trends of Lupus Nephritis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Lupus Nephritis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Lupus Nephritis
- The report provides the segmentation of the Lupus Nephritis epidemiology
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Request for sample pages : https://delveinsight.com/sample-request/lupus-nephritis-epidemiology-forecast
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Lupus Nephritis?
- What are the key findings pertaining to the Lupus Nephritis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Lupus Nephritis across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the Lupus Nephritis?
- What are the currently available treatments of Lupus Nephritis?
Reasons to buy
- The Lupus Nephritis Epidemiology report will allow the user to –
- Develop business strategies by understanding the trends shaping and driving the global Lupus Nephritis market
- Quantify patient populations in the global Lupus Nephritis market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Lupus Nephritis therapeutics in each of the markets covered
- Understand the magnitude of Lupus Nephritis population by its epidemiology
- The Lupus Nephritis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Related Reports:
Lupus Nephritis – Pipeline Insights, 2020
The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.
Lupus Nephritis- Market Insight, Epidemiology and Market Forecast -2030
The Lupus Nephritis market report provides current treatment practices, emerging drugs, Lupus Nephritis market share of the individual therapies, current and forecasted Lupus Nephritis market Size from 2017 to 2030 segmented by seven major markets.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/